Precision BioSciences Files Two New Infringement Lawsuits Against CELLECTIS SA, Requests Permanent Injunction Against Importation of Infringing Materials into U.S.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed two patent infringement lawsuits against Cellectis SA and a number of its affiliates in the U.S. District Court for the Eastern District of North Carolina. The lawsuits seek a ruling that Cellectis’ manufacture, use, sale, and importation of certain engineered meganucleases infringe U.S. Patent Nos. 8,119,381 and 8,119,361, both of which relate to Precision BioSciences’ cutting-edge Directed Nuclease EditorTM genome engineering technology. The lawsuits request monetary damages as well as a permanent injunction preventing Cellectis from making, using, selling, offering for sale, or importing infringing engineered meganucleases in the United States. Precision BioSciences previously announced in October 2011 that it had filed suit against Cellectis for alleged infringement of U.S. Patent No. 8,021,867.

“As pioneers in the field of genome engineering, the Precision BioSciences team has worked tirelessly over many years to develop a broad patent estate to protect the important and highly valuable inventions related to our Directed Nuclease Editor genome engineering technology,” said Matthew Kane, CEO of Precision BioSciences. “We will not tolerate the unauthorized and wrongful use and importation of our inventions and materials.”

About Precision BioSciences

Precision BioSciences’ mission is to continually provide, improve, and enable the world’s most powerful genome engineering technology. Precision’s proprietary Directed Nuclease EditorTM (DNE) technology enables the production of genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.

Precision BioSciences’ vision is to be the conduit through which the world’s greatest genome engineering challenges are solved. Precision has successfully utilized its DNE technology to create innovative products in partnerships with many of the world’s largest biopharmaceutical, agbiotech, and animal research firms. Internally, Precision is developing applications of DNE in biological production and human therapeutics. For additional information, please visit


Precision BioSciences

Chelsea Lynam, 919-314-5512

Back to news